Home ›
Esophageal Cancer Trials ›
NCT05910827
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
This is a Phase Ib/II multi-center, open-label study of HMBD-001 in combination with cetuximab with or without docetaxel in participants with advanced Squamous Cell Cancers
Trial Details
NCT ID NCT05910827
Phase PHASE1 / PHASE2
Sponsor Hummingbird Bioscience
Status RECRUITING
Cancer Type Esophageal Cancer
Interventions HMBD-001 Docetaxel Cetuximab
Locations (sample) Sydney, New South Wales, Australia|-33.86785,151.20732 Westmead, New South Wales, Australia|-33.80383,150.98768 Brisbane, Queensland, Australia|-27.46794,153.02809 Greenslopes, Queensland, Australia|-27.50815,153.04951 Adelaide, South Australia, Australia|-34.92866,138.59863
Key Eligibility Criteria
Ability to understand and be willing to sign an informed consent form Males and females aged over 18 years (or having reached the age of majority according to local laws if the age of majority is \> 18 years of age) Eastern Cooperative Oncology Group (ECOG) status of 0 to 1 Arm B only: Locally advanced or metastatic squamous non-small cell lung cancer for which all available standard of care treatment options have been…
For full eligibility, visit ClinicalTrials.gov .